glutathione mutations in sclc patients Frontiers The Era of Antibody Drug
The Era of Antibody Drug Conjugates in Lung Cancer: Trick or Threat? Differential KEAP1 NRF2 mediated signaling widens the therapeutic window of redox targeting drugs in SCLC therapy Nature Communications Cellular Compartmentalization, Glutathione Transport and Its Relevance in Some Pathologies Antibody drug conjugates: A new twist to overcome EGFR TKIs resistance in non small cell lung cancer ScienceDirect
Pay in 4 interest-free payments of $6.75 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8


